Effect of a Dose-Escalation Regimen for Improving Adherence to Roflumilast in Patients with Chronic Obstructive Pulmonary Disease |
Hwang, Hyunjung
(Division of Pulmonary and Allergy, Department of Internal Medicine, Gachon University Gil Medical Center)
Shin, Ji Young (Division of Pulmonary and Allergy, Department of Internal Medicine, Gachon University Gil Medical Center) Park, Kyu Ree (Division of Pulmonary and Allergy, Department of Internal Medicine, Gachon University Gil Medical Center) Shin, Jae Ouk (Division of Pulmonary and Allergy, Department of Internal Medicine, Gachon University Gil Medical Center) Song, Kyoung-hwan (Division of Pulmonary and Allergy, Department of Internal Medicine, Gachon University Gil Medical Center) Park, Joonhyung (Department of Internal Medicine, Incheon Christian Hospital) Park, Jeong Woong (Division of Pulmonary and Allergy, Department of Internal Medicine, Gachon University Gil Medical Center) |
1 | Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004;364:709-21. DOI |
2 | Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenbroker D, Bethke TD. Roflumilast: an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005;366:563-71. DOI |
3 | Lahu G, Facius A. Application of population pharmacokinetic modeling to explore the impact of alternative roflumilast dosing regimens on tolerability. Int J Clin Pharmacol Ther 2013; 51:832-6. DOI |
4 | Torphy TJ, Barnette MS, Underwood DC, Griswold DE, Christensen SB, Murdoch RD, et al. Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulm Pharmacol Ther 1999;12:131-5. DOI |
5 | Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:347-65. DOI |
6 | Michalski JM, Golden G, Ikari J, Rennard SI. PDE4: a novel target in the treatment of chronic obstructive pulmonary disease. Clin Pharmacol Ther 2012;91:134-42. DOI |
7 | Beghe B, Rabe KF, Fabbri LM. Phosphodiesterase-4 inhibitor therapy for lung diseases. Am J Respir Crit Care Med 2013; 188:271-8. DOI |
8 | Giembycz MA, Newton R. Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective phosphodiesterase inhibitors and novel combination therapies. Handb Exp Pharmacol 2011; (204):415-46. |
9 | Rabe KF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol 2011;163:53-67. DOI |
10 | Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009;374:685-94. DOI |
11 | Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 2001;297:280-90. |
![]() |